Completed PHASE1 INTERVENTIONAL 1-arm NCT01625559

Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy(SMD)

A Phase I, Open-Label, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial(MA09-hRPE) Cells in Patients With Stargardt's Macular Dystrophy(SMD)

Sponsor: CHABiotech CO., Ltd

Conditions Stargardt's Macular Dystrophy

Interventions MA09-hRPE

Updated 8 times since 2017 Last updated: Apr 8, 2024 Started: Sep 30, 2012 Primary completion: Apr 30, 2015 Completion: Apr 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Stargardt's Macular Dystrophy and is currently completed. CHABiotech CO., Ltd leads this study, which shows 8 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
May 2024 — Jul 2024 [monthly]

Completed PHASE1
Mar 2024 — May 2024 [monthly]

Completed PHASE1

Status: Unknown Status → Completed

▶ Show 3 earlier versions

Jan 2021 — Mar 2024 [monthly]

Unknown Status PHASE1
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE1
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE1

First recorded

Sep 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CHABiotech CO., Ltd

Data source: CHABiotech CO., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seongnam-si, South Korea